Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 - Uemura - 2020 - Cancer Science - Wiley Online Library
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Cancers | Free Full-Text | Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Fabio Schutz on Twitter: "JAEVILIN Renal 101 preliminary results presented by Dr. Motzer. Double the ORR with Avelumab+Axitinib, and improved PFS. Overall population and PDL1 positive poliarquia with similar benefit. OS still
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101 - ESMO Open
Dr. Elias reviews Keynote 426 and JAVELIN Renal 101 clinical trials – UT Southwestern Internal Medicine Journal Watch
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Cancers | Free Full-Text | Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
ASCO 2021: Efficacy of Avelumab + Axitinib (A + Ax) Versus Sunitinib (S) by IMDC Risk Group in Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
ASCO GU 2019: JAVELIN Renal 101: Outcomes for Avelumab + Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma (RCC)
Updates ASCO GU 2019 - mRCC
![PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e664af226abec8594ac677be056e2d38fe37bc93/6-Figure1-1.png "PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar")
PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar
Immunotherapy Combinations Revolutionize the Management of Advanced Renal Cell Carcinoma
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma -
Emerging Combination Therapies in Renal-Cell Carcinoma: Applying the Lessons from Clinical Trials to Clinical Practice - Journal of Oncology Navigation & Survivorship
ASCO GU 2020: Depth of Response (DepOR) Analysis and Correlation with Clinical Outcomes from JAVELIN Renal 101
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Request PDF
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Safety and Efficacy Data: The JAVELIN Renal 101 Trial
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) - UROONCO Kidney Cancer
Immunotherapy Strategies in Renal Cell Carcinoma - The ASCO Post
ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. - Abstract - Europe PMC
